Abstract:Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide, with high morbidity and mortality. Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma and the majority (~80%) of hepatocellular carcinoma patients in China exhibit co-morbidity with HBV-associated liver cirrhosis. The goal of reliable early diagnostic and prognostic techniques for HBV-associated HCC remains unrealized. The aim of the present study was to explore the efficacy of serum high-sensitivity C-reactive protein (hs-CRP) tests in the early diagnosis of HCC in patients with HBV-associated liver cirrhosis. A cohort of 493 patients with HBV-associated liver disease was divided into three groups: Chronic HBV (CHB) group; liver cirrhosis without HCC (LC) group; and liver cirrhosis with HCC (HCC) group. A further 47 healthy individuals comprised the healthy control (CN) group. Comparative analyses of clinical symptoms, histopathology, ultrasound imagery, computed tomography, magnetic resonance imaging, biochemistry [α-fetoprotein (AFP) and liver function enzymes], and hs-CRP tests were conducted across these four groups. Immunohistochemical analysis showed that CRP is strongly expressed in HCC tumor tissue, but is not expressed elsewhere. Analyses of the correlations between serum hs-CRP levels and HCC clinical parameters indicated that there was no correlation between serum hs-CRP levels, tumor Edmondson grade, tumor-node-metastasis stage and AFP status. Serum hs-CRP and AFP levels were found to be significantly elevated in the HCC group compared to those in the LC, CHB and CN groups (P<0.01). Receiver operator characteristic analysis showed that measurement of serum hs-CRP could differentiate HCC from HBV-associated liver cirrhosis, as well as increase the accuracy of HCC diagnoses. Additionally, measurement of hs-CRP and AFP together improved diagnostic accuracy for HCC compared with either test alone. Serum hs-CRP could have potential as an effective diagnostic tool to complement AFP in diagnosing HCC and improving the identification of AFP-negative HCC in patients with HBV-associated liver cirrhosis. The present findings may facilitate the earlier diagnosis of hepatocellular carcinoma, permitting more effective treatment and a broader spectrum of treatment modalities for patients with advanced hepatic disease.

Study on the diagnostic value of sera extracellular cAMP-dependent protein kinase (ECPKA) level in patients with Hepatocellular carcinoma

Combined determination of serum DCP, GPC3 and HSP70 in diagnosis of AFP-negative primary liver carcinoma

Value of combined measurement of serum alpha-fetoprotein,Dickkopf-1,and cytoskeleton-associated protein 4 in diagnosis of hepatocellular carcinoma

Assessment of High-Sensitivity C-reactive Protein Tests for the Diagnosis of Hepatocellular Carcinoma in Patients with Hepatitis B-associated Liver Cirrhosis

Application of Serum Protein Induced by Vitamin K Absence or Antagonist-ⅱ in Clinical Diagnosis of Hepatocellular Carcinoma

Role of TFCP2/YAP transcriptional complex co-regulated protein CPE for the diagnosis of hepatocellular carcinoma

Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to α fetoprotein.

Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma

Diagnostic potential of Dickkopf-1 for heptocellular carcinoma using magnetic solid phase chemiluminescent immunoassay

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis

[Application of Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma].

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

Diagnostic Value Of Serum Haptoglobin Protein As Hepatocellular Carcinoma Candidate Marker Complementary To Alpha Fetoprotein

Evaluation of hepatocellular carcinoma by combined detection of serum AFP-IgM complex and liver function

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.

Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma

Evaluation of α-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma.

The Prognostic Significance of Preoperative Serum Levels of Extracellular Matrix Protein 1 in Patients with Hepatocellular Carcinoma

Diagnostic value of Golgi protein 73 alone and in combination with alpha fetoprotein in hepatocellular carcinoma

Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma

The Value of Serum Glypican-3 Level in Aided Diagnosis of Patients with Primary Hepatocellular Carcinoma